Colonic Dendritic Cells, Intestinal Inflammation, and T Cell-Mediated Bone Destruction Are Modulated by Recombinant Osteoprotegerin

Immunity

Volumn 19, Issue 6, 2003, Pages 849-861

  Ashcroft, A J ^a   Cruickshank, S M ^a   Croucher, P I ^b   Perry, M J ^c   Rollinson, S ^a   Lippitt, J M ^d   Child, J A ^a   Dunstan, C ^e,g   Felsburg, P J ^f   Morgan, G J ^a   Carding, S R ^a  

^a UNIVERSITY OF LEEDS   (United Kingdom)

^b UNIVERSITY OF SHEFFIELD   (United Kingdom)

^c UNIVERSITY OF BRISTOL   (United Kingdom)

^d UNIVERSITY OF SHEFFIELD   (United Kingdom)

^e AMGEN INC   (United States)

^f UNIVERSITY OF PENNSYLVANIA   (United States)

^g Department of Microbiology and Infectious Diseases   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 2; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; RECEPTOR PROTEIN; RECOMBINANT OSTEOPROTEGERIN; RECOMBINANT PROTEIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUTOIMMUNITY; BONE DESTRUCTION; BONE DISEASE; BONE TURNOVER; CELL COUNT; CELL SURVIVAL; COLITIS; CONTROLLED STUDY; DENDRITIC CELL; DISEASE ASSOCIATION; DISEASE MODEL; ENTERITIS; INTESTINE CELL; MOUSE; NONHUMAN; OSTEOPENIA; PRIORITY JOURNAL; PROTEIN DEFICIENCY; PROTEIN PROTEIN INTERACTION; PROTEIN SYNTHESIS; QUANTITATIVE ANALYSIS; REGULATORY MECHANISM; T LYMPHOCYTE;

EID: 10744220366     PISSN: 10747613     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1074-7613(03)00326-1     Document Type: Article

References (52)

1. Anderson D.M., Maraskovsky E., Billingsley W.L., Dougall W.C., Tometsko M.E., Roux E.R., Teepe M.C., DuBose R.F., Cosman D., Galibert L. A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function. Nature. 390:1997;175-179.
2. Atkins G.J., Bouralexis S., Haynes D.R., Graves S.E., Geary S.M., Evdokiou A., Zannettino A.C., Hay S., Findlay D.M. Osteoprotegerin inhibits osteoclast formation and bone resorbing activity in giant cell tumors of bone. Bone. 28:2001;370-377.
3. Bekker P.J., Holloway D., Nakanishi A., Arrighi M., Leese P.T., Dunstan C.R. The effect of a single dose of osteoprotegerin in postmenopausal women. J. Bone Miner. Res. 16:2001;348-360.
4. Bell S.J., Rigby R., English N., Mann S.D., Knight S.C., Kamm M.A., Stagg A.J. Migration and maturation of human colonic dendritic cells. J. Immunol. 166:2001;4958-4967.
5. Contractor N.V., Bassiri H., Reya T., Park A.Y., Baumgart D.C., Wasik M.A., Emerson S.G., Carding S.R. Lymphoid hyperplasia, autoimmunity, and compromised intestinal intraepithelial lymphocyte development in colitis-free gnotobiotic IL-2-deficient mice. J. Immunol. 160:1998;385-394.
6. Croucher P.I., Shipman C.M., Lippitt J., Perry M., Asosingh K., Hijzen A., Brabbs A.C., van Beek E.J., Holen I., Skerry T.M.et al. Osteoprotegerin inhibits the development of osteolytic bone disease in multiple myeloma. Blood. 98:2001;3534-3540.
7. de Jong D.J., Corstens F.H., Mannaerts L., van Rossum L.G., Naber A.H. Corticosteroid-induced osteoporosis. does it occur in patients with Crohn's disease? Am. J. Gastroenterol. 97:2002;2011-2015.
8. Dougall W.C., Glaccum M., Charrier K., Rohrbach K., Brasel K., De Smedt T., Daro E., Smith J., Tometsko M.E., Maliszewski C.R.et al. RANK is essential for osteoclast and lymph node development. Genes Dev. 13:1999;2412-2424.
9. Espinoza-Delgado I., Bosco M.C., Musso T., Gusella G.L., Longo D.L., Varesio L. Interleukin-2 and human monocyte activation. J. Leukoc. Biol. 57:1995;13-19.
10. Fickling W.E., McFarlane X.A., Bhalla A.K., Robertson D.A. The clinical impact of metabolic bone disease in coeliac disease. Postgrad. Med. J. 77:2001;33-36.
11. Fu Y.X., Chaplin D.D. Development and maturation of secondary lymphoid tissues. Annu. Rev. Immunol. 17:1999;399-433.
12. Gowen M., Mundy G.R. Actions of recombinant interleukin 1, interleukin 2, and interferon-gamma on bone resorption in vitro. J. Immunol. 136:1986;2478-2482.
13. Grewal I.S., Flavell R.A. CD40 and CD154 in cell-mediated immunity. Annu. Rev. Immunol. 16:1998;111-135.
14. Honore P., Luger N.M., Sabino M.A., Schwei M.J., Rogers S.D., Mach D.B., O'Keefe P.F., Ramnaraine M.L., Clohisy D.R., Mantyh P.W. Osteoprotegerin blocks bone cancer-induced skeletal destruction, skeletal pain and pain-related neurochemical reorganization of the spinal cord. Nat. Med. 6:2000;521-528.
15. Horwood N.J., Kartsogiannis V., Quinn J.M., Romas E., Martin T.J., Gillespie M.T. Activated T lymphocytes support osteoclast formation in vitro. Biochem. Biophys. Res. Commun. 265:1999;144-150.
16. Josien R., Wong B.R., Li H.L., Steinman R.M., Choi Y. TRANCE, a TNF family member, is differentially expressed on T cell subsets and induces cytokine production in dendritic cells. J. Immunol. 162:1999;2562-2568.
17. Josien R., Li H.L., Ingulli E., Sarma S., Wong B.R., Vologodskaia M., Steinman R.M., Choi Y. TRANCE, a tumor necrosis factor family member, enhances the longevity and adjuvant properties of dendritic cells in vivo. J. Exp. Med. 191:2000;495-502.
18. Kirchgatterer A., Wenzl H.H., Aschl G., Hinterreiter M., Stadler B., Hinterleitner T.A., Petritsch W., Knoflach P. Examination, prevention and treatment of osteoporosis in patients with inflammatory bowel disease. recommendations and reality Acta Med. Austriaca. 29:2002;120-123.
19. Klaus J., Armbrecht G., Steinkamp M., Bruckel J., Rieber A., Adler G., Reinshagen M., Felsenberg D., von Tirpitz C. High prevalence of osteoporotic vertebral fractures in patients with Crohn's disease. Gut. 51:2002;654-658.
20. Kong Y.Y., Feige U., Sarosi I., Bolon B., Tafuri A., Morony S., Capparelli C., Li J., Elliott R., McCabe S.et al. Activated T cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligand. Nature. 402:1999;304-309. a.
21. Kong Y.Y., Yoshida H., Sarosi I., Tan H.L., Timms E., Capparelli C., Morony S., Oliveira-dos-Santos A.J., Van G., Itie A.et al. OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis. Nature. 397:1999;315-323. b.
22. Krajina T., Leithauser F., Moller P., Trobonjaca Z., Reimann J. Colonic lamina propria dendritic cells in mice with CD4+ T cell-induced colitis. Eur. J. Immunol. 33:2003;1073-1083.
23. Kramer S., Schimpl A., Hunig T. Immunopathology of interleukin (IL) 2-deficient mice. thymus dependence and suppression by thymus-dependent cells with an intact IL-2 gene J. Exp. Med. 182:1995;1769-1776.
24. Lacey D.L., Timms E., Tan H.L., Kelley M.J., Dunstan C.R., Burgess T., Elliott R., Colombero A., Elliott G., Scully S.et al. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell. 93:1998;165-176.
25. Lamb E.J., Wong T., Smith D.J., Simpson D.E., Coakley A.J., Moniz C., Muller A.F. Metabolic bone disease is present at diagnosis in patients with inflammatory bowel disease. Aliment. Pharmacol. Ther. 16:2002;1895-1902.
26. Li J., Sarosi I., Yan X.Q., Morony S., Capparelli C., Tan H.L., McCabe S., Elliott R., Scully S., Van G.et al. RANK is the intrinsic hematopoietic cell surface receptor that controls osteoclastogenesis and regulation of bone mass and calcium metabolism. Proc. Natl. Acad. Sci. USA. 97:2000;1566-1571.
27. Locksley R.M., Killeen N., Lenardo M.J. The TNF and TNF receptor superfamilies. integrating mammalian biology Cell. 104:2001;487-501.
28. Mizuno A., Amizuka N., Irie K., Murakami A., Fujise N., Kanno T., Sato Y., Nakagawa N., Yasuda H., Mochizuki S.et al. Severe osteoporosis in mice lacking osteoclastogenesis inhibitory factor/osteoprotegerin. Biochem. Biophys. Res. Commun. 247:1998;610-615.
29. Morony S., Capparelli C., Sarosi I., Lacey D.L., Dunstan C.R., Kostenuik P.J. Osteoprotegerin inhibits osteolysis and decreases skeletal tumor burden in syngeneic and nude mouse models of experimental bone metastasis. Cancer Res. 61:2001;4432-4436.
30. Nosaka K., Miyamoto T., Sakai T., Mitsuya H., Suda T., Matsuoka M. Mechanism of hypercalcemia in adult T-cell leukemia. overexpression of receptor activator of nuclear factor kappaB ligand on adult T-cell leukemia cells Blood. 99:2002;634-640.
31. Oelzner P., Franke S., Muller A., Hein G., Stein G. Relationship between soluble markers of immune activation and bone turnover in post-menopausal women with rheumatoid arthritis. Rheumatology (Oxford). 38:1999;841-847.
32. Ogata Y., Kukita A., Kukita T., Komine M., Miyahara A., Miyazaki S., Kohashi O. A novel role of IL-15 in the development of osteoclasts. inability to replace its activity with IL-2 J. Immunol. 162:1999;2754-2760.
33. Reya T., Contractor N.V., Couzens M.S., Wasik M.A., Emerson S.G., Carding S.R. Abnormal myelocytic cell development in interleukin-2 (IL-2)-deficient mice. evidence for the involvement of IL-2 in myelopoiesis Blood. 91:1998;2935-2947.
34. Ries W.L., Seeds M.C., Key L.L. Interleukin-2 stimulates osteoclastic activity. increased acid production and radioactive calcium release J. Periodontal Res. 24:1989;242-246.
35. Rifas L., Arackal S., Weitzmann M.N. Inflammatory T cells rapidly induce differentiation of human bone marrow stromal cells into mature osteoblasts. J. Cell. Biochem. 88:2003;650-659.
36. Sadlack B., Merz H., Schorle H., Schimpl A., Feller A.C., Horak I. Ulcerative colitis-like disease in mice with a disrupted interleukin-2 gene. Cell. 75:1993;253-261.
37. Schimpl A., Berberich I., Kneitz B., Kramer S., Santner-Nanan B., Wagner S., Wolf M., Hunig T. IL-2 and autoimmune disease. Cytokine Growth Factor Rev. 13:2002;369-378.
38. Schneider G.B., Relfson M. Effects of interleukin-2 on bone resorption and natural immunity in osteopetrotic (ia) rats. Lymphokine Cytokine Res. 13:1994;335-341.
39. Schorle H., Holtschke T., Hunig T., Schimpl A., Horak I. Development and function of T cells in mice rendered interleukin-2 deficient by gene targeting. Nature. 352:1991;621-624.
40. Schultz C., Klouche M., Friedrichsdorf S., Richter N., Kroehnert B., Bucsky P. Langerhans cell histiocytosis in children. does soluble interleukin-2-receptor correlate with both disease extent and activity? Med. Pediatr. Oncol. 31:1998;61-65.
41. Seymour G.J., Cole K.L., Powell R.N., Lewins E., Cripps A.W., Clancy R.L. Interleukin-2 production and bone-resorption activity in vitro by unstimulated lymphocytes extracted from chronically-inflamed human periodontal tissues. Arch. Oral Biol. 30:1985;481-484.
42. Shipman C.M., Croucher P.I. Osteoprotegerin is a soluble decoy receptor for tumor necrosis factor-related apoptosis-inducing ligand/Apo2 ligand and can function as a paracrine survival factor for human myeloma cells. Cancer Res. 63:2003;912-916.
43. Simonet W.S., Lacey D.L., Dunstan C.R., Kelley M., Chang M.S., Luthy R., Nguyen H.Q., Wooden S., Bennett L., Boone T.et al. Osteoprotegerin. a novel secreted protein involved in the regulation of bone density Cell. 89:1997;309-319.
44. Stagg A.J., Hart A.L., Knight S.C., Kamm M.A. The dendritic cell. its role in intestinal inflammation and relationship with gut bacteria Gut. 52:2003;1522-1529.
45. Theill L.E., Boyle W.J., Penninger J.M. Rank-l and rank. T cells, bone loss, and mammalian evolution Annu. Rev. Immunol. 20:2002;795-823.
46. Udagawa N., Kotake S., Kamatani N., Takahashi N., Suda T. The molecular mechanism of osteoclastogenesis in rheumatoid arthritis. Arthritis Res. 4:2002;281-289.
47. Weitzmann M.N., Cenci S., Rifas L., Haug J., Dipersio J., Pacifici R. T cell activation induces human osteoclast formation via receptor activator of nuclear factor kappaB ligand-dependent and -independent mechanisms. J. Bone Miner. Res. 16:2001;328-337.
48. Williamson E., Bilsborough J.M., Viney J.L. Regulation of mucosal dendritic cell function by receptor activator of NF-kappa B (RANK)/RANK ligand interactions. impact on tolerance induction J. Immunol. 169:2002;3606-3612.
49. Wong B.R., Josien R., Lee S.Y., Sauter B., Li H.L., Steinman R.M., Choi Y. TRANCE (tumor necrosis factor [TNF]-related activation-induced cytokine), a new TNF family member predominantly expressed in T cells, is a dendritic cell-specific survival factor. J. Exp. Med. 186:1997;2075-2080.
50. Yun T.J., Tallquist M.D., Aicher A., Rafferty K.L., Marshall A.J., Moon J.J., Ewings M.E., Mohaupt M., Herring S.W., Clark E.A. Osteoprotegerin, a crucial regulator of bone metabolism, also regulates B cell development and function. J. Immunol. 166:2001;1482-1491.
51. Zhang J., Dai J., Qi Y., Lin D.L., Smith P., Strayhorn C., Mizokami A., Fu Z., Westman J., Keller E.T. Osteoprotegerin inhibits prostate cancer-induced osteoclastogenesis and prevents prostate tumor growth in the bone. J. Clin. Invest. 107:2001;1235-1244.
52. Zheng L., Trageser C.L., Willerford D.M., Lenardo M.J. T cell growth cytokines cause the superinduction of molecules mediating antigen-induced T lymphocyte death. J. Immunol. 160:1998;763-769.